Truist Securities Assumes argenx SE (ARGX) at Buy

Truist Securities analyst Danielle Brill assumes coverage on argenx SE (NASDAQ: ARGX) with a Buy rating and a price target of $918.00.

The analyst comments "We assume coverage of ARGX with an unchanged BUY rating but raise our price target to $918 (from $700). In our view, ARGX represents one of the most compelling investment opportunities in the biotech sector given the (1) strong revenue growth outlook for current Vyvgart franchise in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), (2) several additional growth levers for Vyvgart, w/ potential value inflection from the 2 most advanced programs next year, (3) diversification & further growth potential from empasiprubart w/ Ph 3 data approaching next year, and (4) notable relative valuation gap vs its peers."

For an analyst ratings summary and ratings history on argenx SE click here. For more ratings news on argenx SE click here.

Shares of argenx SE closed at $756.39 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy